New spiro-indeno[1,2-b]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights

References

• Horiuchi D, Huskey NE, Kusdra L, Wohlbold L, Merrick KA, Zhang C, Creasman KJ, Shokat KM, Fisher RP, Goga A. Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci USA. 2012;109(17):E1019–E1027.
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003;3(3):233–245.
   PubMed Web of Science ®Google Scholar
• Yang L, Fang D, Chen H, Lu Y, Dong Z, Ding HF, Jing Q, Su SB, Huang S. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget. 2015;6(25):20801–20812.
   PubMedGoogle Scholar
• Sun H, Yin M, Hao D, Shen Y. Anti-cancer activity of Catechin against A549 Lung Carcinoma cells by induction of cyclin kinase inhibitor p21 and suppression of cyclin E1 and P–AKT. Appl Sci. 2020;10(6):2065.
   Google Scholar
• Ullah MA, Farzana M, Islam MS, Moni R, Zohora US, Rahman MS. Identification of the prognostic and therapeutic values of cyclin E1 (CCNE1) gene expression in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma: a database mining approach. Heliyon. 2022; 8(9):e10367.
   PubMed Web of Science ®Google Scholar
• Barriere C, Santamaria D, Cerqueira A, Galan J, Martin A, Ortega S, Malumbres M, Dubus P, Barbacid M. Mice thrive without Cdk4 and Cdk2. Mol Oncol. 2007;1(1):72–83.
   PubMed Web of Science ®Google Scholar
• Beale G, Haagensen EJ, Thomas HD, Wang LZ, Revill CH, Payne SL, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, et al. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer. 2016;115(6):682–690.
   PubMed Web of Science ®Google Scholar
• Bolin S, Borgenvik A, Persson CU, Sundstrom A, Qi J, Bradner JE, Weiss WA, Cho YJ, Weishaupt H, Swartling FJ. Combined BET Bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene. 2018;37(21):2850–2862.
   PubMed Web of Science ®Google Scholar
• Stefanikova A, Klacanova K, Pilchova I, Hatok J, Racay P. Cyclin-dependent Kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 Mimetic ABT-737. Gen Physiol Biophys. 2017;36(5):539–547.
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, et al. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. Mol Oncol. 2018;12(3):287–304.
   PubMed Web of Science ®Google Scholar
• Azimi A, Caramuta S, Seashore-Ludlow B, Bostrom J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, et al. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. Mol Syst Biol. 2018;14(3):e7858.
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301–2313.
   PubMed Web of Science ®Google Scholar
• Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018; 10(10):1758835918786451.
   Google Scholar
• Schang LM. Advances on Cyclin-dependent Kinases (CDKs) as Novel targets for antiviral drugs. Curr Drug Targets Infect Disord. 2005;5(1):29–37.
   PubMedGoogle Scholar
• Lee KH, Lee SJ, Lee HJ, Choi GE, Jung YH, Kim DI, Gabr AA, Ryu JM, Han HJ. Amyloid beta1-42 (Abeta1-42) induces the CDK2-mediated phosphorylation of Tau through the activation of the mTORC1 signaling pathway while promoting neuronal cell death. Front Mol Neurosci. 2017;10:229.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting Cyclin-dependent Kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146.
   PubMed Web of Science ®Google Scholar
• Razga F, Nemethova V. Selective therapeutic intervention: a challenge against off-target effects. Trends Mol Med. 2017;23(8):671–674.
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017; 173:83–105.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10(12 Pt 2):4270s–4275s.
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 2007;96(1):29–37.
   PubMed Web of Science ®Google Scholar
• Jackson RC, Barnett AL, McClue SJ, Green SR. Seliciclib, a cell cycle modulator that acts through the inhibition of cyclin-dependent kinases. Expert Opin Drug Discov. 2008;3(1):131–143.
   PubMed Web of Science ®Google Scholar
• Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem. 2019;62(9):4233–4251.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Mustachio LM, Rodriguez-Canales J, et al. Next-generation CDK2/9 inhibitors and anaphase catastrophe in lung cancer. J Natl Cancer Inst. 2017;109(6):109.
   Google Scholar
• Kodym E, Kodym R, Reis AE, Habib AA, Story MD, Saha D. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer. 2009;66 (1):37–47.
   PubMed Web of Science ®Google Scholar
• Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S, Bristow RG, Saha D. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys. 2012;84(4):e507–e514.
   PubMed Web of Science ®Google Scholar
• Al‐Jassas RM, Islam MS, Al-Majid AM, Nafie MS, Haukka M, Rahman AM, Alayyaf AMA, Barakat A. Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities. Arch Pharm. 2023;356(8):e2300185.
   PubMed Web of Science ®Google Scholar
• Meng X, Zhu X, Ji J, Zhong H, Li X, Zhao H, Xie G, Wang K, Shu H, Wang X. Erdafitinib inhibits tumorigenesis of human lung adenocarcinoma A549 by inducing S-phase cell-cycle arrest as a CDK2 inhibitor. Molecules. 2022;27(19):6733.
   PubMed Web of Science ®Google Scholar
• Nugiel DA, Vidwan A, Etzkorn AM, Rossi KA, Benfield PA, Burton CR, Cox S, Doleniak D, Seitz SP. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. J Med Chem. 2002;45(24):5224–5232.
   PubMed Web of Science ®Google Scholar
• Shimomura I, Yokoi A, Kohama I, Kumazaki M, Tada Y, Tatsumi K, Ochiya T, Yamamoto Y. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. Cancer Lett. 2019;451:11–22.
   PubMed Web of Science ®Google Scholar
• El-Hameed RH, Fatahala SS, Sayed AI. Synthesis of some Novel Benzimidazole derivatives as anticancer agent and evaluation for CDK2 inhibition activity. Med Chem. 2022;18(2):238–248.
   PubMed Web of Science ®Google Scholar
• Zhong W, Lalovic B, Zhan J. AG-024322, a novel cyclindependent kinase (CDK) inhibitor. Health. 2009;1(4):249–262.
   Google Scholar
• Sculier J, Ghisdal L, Berghmans T, Branle F, Lafitte JJ, Vallot F, Meer AP, Lemaitre F, Steels E, Burniat A, et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer. 2001;84(9):1150–1155.
   PubMed Web of Science ®Google Scholar
• Barakat A, Alshahrani S, Al-Majid AM, Alamary AS, Haukka M, Abu-Serie MM, Dömling A, Mazyed EA, Badria FA, El-Senduny FF. Novel spirooxindole based benzimidazole scaffold: in vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma. Bioorg Chem. 2022;129:106124.
   PubMed Web of Science ®Google Scholar
• Alshahrani S, Al-Majid AM, Ali M, Alamary AS, Abu-Serie MM, Dömling A, Shafiq M, Ul-Haq Z, Barakat A. Rational design, synthesis, separation, and characterization of new spiroxindoles combined with benzimidazole scaffold as an MDM2 inhibitor. Separations. 2023;10(4):225.
   Web of Science ®Google Scholar
• CrysAlisPro. Rikagu Oxford Diffraction. Yarnton, Oxfordshire, England: Rikagu Oxford Diffraction Inc.; 2020.
   Google Scholar
• Sheldrick GM. SHELXT - Integrated space-group and crystal-structure determination. Acta Crystallogr A Found Adv 2015;71:3–8.
   Google Scholar
• Sheldrick GM. Crystal structure refinement with SHELXL. Acta Crystallogr C Struct Chem. 2015;71(Pt 1):3–8.
   PubMed Web of Science ®Google Scholar
• Hübschle CB, Sheldrick GM, Dittrich B. ShelXle: a Qt graphical user interface for SHELXL. J Appl Crystallogr. 2011;44(Pt 6):1281–1284.
   PubMedGoogle Scholar
• Domingo LR. Molecular electron density theory: a modern view of reactivity in organic chemistry. Molecules. 2016;21(10):1319.
   PubMed Web of Science ®Google Scholar
• Parr RG, Yang W. Density functional theory of atoms and molecules. New York: Oxford University Press; 1989.
   Google Scholar
• Domingo LR, Ríos-Gutiérrez M, Pérez P. Applications of the conceptual density functional indices to organic chemistry reactivity. Molecules. 2016;21(6):748.
   PubMed Web of Science ®Google Scholar
• Domingo LR, Ríos-Gutiérrez M. Application of reactivity indices in the study of polar Diels–alder reactions. In: Liu S, editors, Conceptual density functional theory: towards a new chemical reactivity theory. Weinheim, German: WILEY-VCH GmbH; 2022, Volume 2, p. 481–502.
   Google Scholar
• Parr RG, Pearson RG. Absolute hardness: companion parameter to absolute electronegativity. J Am Chem Soc. 1983;105(26):7512–7516.
   Web of Science ®Google Scholar
• Domingo LR. A new C–C bond formation model based on the quantum chemical topology of electron density. RSC Adv. 2014;4(61):32415–32428.
   Web of Science ®Google Scholar
• Doming LR, Ríos-Gutiérrez M. A useful classification of organic reactions based on the flux of the electron density. Sci Rad. 2023;2(1):1–24.
   Google Scholar
• Parr RG, Szentpaly LV, Liu S. Electrophilicity index. J Am Chem Soc. 1999;121(9):1922–1924.
   Web of Science ®Google Scholar
• Domingo LR, Chamorro E, Pérez P. Understanding the reactivity of captodative ethylenes in polar cycloaddition reactions. A theoretical study. J Org Chem. 2008;73(12):4615–4624.
   PubMed Web of Science ®Google Scholar
• Evans MG, Polanyi M. Some applications of the transition state method to the calculation of reaction velocities, especially in solution. Trans Faraday Soc. 1935;31:875–894.
   Google Scholar
• Fukui K. Formulation of the reaction coordinate. J Phys Chem. 1970;74(23):4161–4163.
   Web of Science ®Google Scholar
• Domingo LR, Sáez JA, Zaragozá RJ, Arnó M. Understanding the participation of Quadricyclane as nucleophile in polar cycloadditions toward electrophilic molecules. J Org Chem. 2008;73(22):8791–8799.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Nafie MS, Kishk SM, Mahgoub S, Amer AM. Quinoline‐based thiazolidinone derivatives as potent cytotoxic and apoptosis‐inducing agents through EGFR inhibition. Chem Biol Drug Des. 2022;99(4):547–560.
   PubMed Web of Science ®Google Scholar
• Shawish I, Nafie MS, Barakat A, Aldalbahi A, Al-Rasheed HH, Ali M, Alshaer W, Al Zoubi M, Al Ayoubi S, De la Torre BG, et al. Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors. Front Chem. 2022; 10:1078163.
   PubMed Web of Science ®Google Scholar
• Dawood KM, Raslan MA, Abbas AA, Mohamed BE, Abdellattif MH, Nafie MS, Hassan MK. Novel Bis-Thiazole derivatives: synthesis and potential cytotoxic activity through apoptosis with molecular docking approaches. Front Chem. 2021;9:694870.
   PubMed Web of Science ®Google Scholar
• Chai J-D, Head-Gordon M. Long-range corrected hybrid density functionals with damped atom–atom dispersion corrections. Phys Chem Chem Phys. 2008;10(44):6615–6620.
   PubMed Web of Science ®Google Scholar
• Hehre MJ, Radom L, Schleyer PR, Pople J. Ab initio molecular orbital theory. New York: Wiley; 1986.
   Google Scholar
• Tomasi J, Persico M. Molecular interactions in solution: and overview of methods based on continuous distributions of the solvent. Chem Rev. 1994;94(7):2027–2094.
   Web of Science ®Google Scholar
• Simkin. BYa, Sheikhet II. Quantum chemical and statistical theory of solutions– computational approach. London: Ellis Horwood; 1995.
   Google Scholar
• Cossi M, Barone V, Cammi R, Tomasi J. Ab initio study of solvated molecules: a new implementation of the polarizable continuum model. Chem Phys Lett. 1996;255(4–6):327–335.
   Web of Science ®Google Scholar
• Cances E, Mennucci B, Tomasi J. A new integral equation formalism for the polarizable continuum model: theoretical background and applications to isotropic and anisotropic dielectrics. J. Chem. Phys. 1997;107(8):3032–3041.
   Web of Science ®Google Scholar
• Barone V, Cossi M, Tomasi J. Geometry optimization of molecular structures in solution by the polarizable continuum model. J Comput Chem. 1998;19(4):404–417.
   Web of Science ®Google Scholar
• Reed AE, Weinstock RB, Weinhold F. Natural population analysis. J Chem Phys. 1985;83(2):735–746.
   Web of Science ®Google Scholar
• Reed AE, Curtiss LA, Weinhold F. Intermolecular interactions from a natural bond orbital, donor-acceptor viewpoint. Chem Rev. 1988;88(6):899–926.
   Web of Science ®Google Scholar
• Frisch MJ. Gaussian 16, Revision A.03. Wallingford CT: Gaussian, Inc.; 2016.
   Google Scholar
• De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin‐dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 1997;243(1–2):518–526.
   PubMedGoogle Scholar
• “Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2019.” 2019.
   Google Scholar
• Case DA, Aktulga HM, Belfon K, Ben-Shalom IY, Berryman JT, et al. Amber 2023. San Francisco: University of California. 2023.
   Google Scholar
• Khalil R, Ashraf S, Khalid A, Ul-Haq Z. Exploring Novel N-Myristoyltransferase inhibitors: a molecular dynamics simulation approach. ACS Omega. 2019;4(9):13658–13670.
   PubMed Web of Science ®Google Scholar
• Roe DR, Cheatham TE. III PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9(7):3084–3095.
   PubMed Web of Science ®Google Scholar